The Leukotrienes: Immune-Modulating Lipid Mediators of Disease

Advances in Immunology

Volumn 116, Issue , 2012, Pages 51-92

  Di Gennaro, Antonio ^a   Haeggström, Jesper Z ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Arachidonic acid; Cardiovascular diseases; Immune responses; Leukocytes; Leukotrienes

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; AM 103; AMELUBANT; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN INHIBITOR; BESTATIN; CAPTOPRIL; CYSTEINYL LEUKOTRIENE RECEPTOR 1; CYSTEINYL LEUKOTRIENE RECEPTOR 2; ETALOCIB; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 17; LEUKOTRIENE; LEUKOTRIENE A4 HYDROLASE; LEUKOTRIENE B4 RECEPTOR; LEUKOTRIENE B4 RECEPTOR 1; LEUKOTRIENE B4 RECEPTOR 2; LEUKOTRIENE C4 SYNTHASE; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; MOXILUBANT; PRANLUKAST; PURINERGIC P2Y12 RECEPTOR; QUIFLAPON; SA 6541; SC 57461A; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZAFIRLUKAST; ZILEUTON;

ABDOMINAL AORTA ANEURYSM; ACUTE CORONARY SYNDROME; ADAPTIVE IMMUNITY; ALLERGIC ASTHMA; ALLERGIC REACTION; ALLERGIC RHINITIS; ARTICLE; ASTHMA; ATHEROSCLEROSIS; BIOSYNTHESIS; CARDIOVASCULAR DISEASE; CELL ADHESION; CEREBROVASCULAR ACCIDENT; CHEMOTAXIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; ENTERITIS; ENZYME ACTIVATION; ENZYME ACTIVITY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; LEUKOCYTE ACTIVATION; MICROCIRCULATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSORIASIS; RESPIRATORY SYSTEM; RHEUMATOID ARTHRITIS; SMOOTH MUSCLE CONTRACTION;

EID: 84867341631     PISSN: 00652776     EISSN: 15578445     Source Type: Book Series    
DOI: 10.1016/B978-0-12-394300-2.00002-8     Document Type: Chapter

References (183)

1. Adamek A., Jung S., Dienesch C., Laser M., Ertl G., Bauersachs J., et al. Role of 5-lipoxygenase in myocardial ischemia-reperfusion injury in mice. European Journal of Pharmacology 2007, 571:51-54.
2. Ago H., Kanaoka Y., Irikura D., Lam B.K., Shimamura T., Austen K.F., et al. Crystal structure of a human membrane protein involved in cysteinyl leukotriene biosynthesis. Nature 2007, 448:609-612.
3. Ahluwalia N., Lin A.Y., Tager A.M., Pruitt I.E., Anderson T.J., Kristo F., et al. Inhibited aortic aneurysm formation in BLT1-deficient mice. The Journal of Immunology 2007, 179:691-697.
4. 4 receptor antagonism reduces monocytic foam cells in mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2002, 22:443-449.
5. Allen S., Dashwood M., Morrison K., Yacoub M. Differential leukotriene constrictor responses in human atherosclerotic coronary arteries. Circulation 1998, 97:2406-2413.
6. Assimes T.L., Knowles J.W., Priest J.R., Basu A., Volcik K.A., Southwick A., et al. Common polymorphisms of ALOX5 and ALOX5AP and risk of coronary artery disease. Human Genetics 2008, 123:399-408.
7. 4 puzzle: Finding the missing pieces and revealing the pathobiologic implications. The Journal of Allergy and Clinical Immunology 2009, 124:406-414.
8. Barajas-Espinosa A., Ni N.C., Yan D., Zarini S., Murphy R.C., Funk C.D. The cysteinyl leukotriene 2 receptor mediates retinal edema and pathological neovascularization in a murine model of oxygen-induced retinopathy. FASEB Journal 2011, 26:1100-1109.
9. Barajas-Espinosa A., Ochoa-Cortes F., Moos M.P., Ramirez F.D., Vanner S.J., Funk C.D. Characterization of the cysteinyl leukotriene 2 receptor in novel expression sites of the gastrointestinal tract. The American Journal of Pathology 2011, 178:2682-2689.
10. Barrett N.A., Maekawa A., Rahman O.M., Austen K.F., Kanaoka Y. Dectin-2 recognition of house dust mite triggers cysteinyl leukotriene generation by dendritic cells. Journal of Immunology 2009, 182:1119-1128.
11. Barrett N.A., Rahman O.M., Fernandez J.M., Parsons M.W., Xing W., Austen K.F., et al. Dectin-2 mediates Th2 immunity through the generation of cysteinyl leukotrienes. The Journal of Experimental Medicine 2011, 208:593-604.
12. Barrett A.J., Rawlings N.D., Woessner J.F. Handbook of proteolytic enzymes 1998, Academic Press, San Diego.
13. Bernstein J.A., Liu N., Knorr B.A., Smugar S.S., Hanley W.D., Reiss T.F., et al. MK-0633, a potent 5-lipoxygenase inhibitor, in chronic obstructive pulmonary disease. Respiratory Medicine 2011, 105:392-401.
14. 4 receptor antagonist. The Journal of Pharmacology and Experimental Therapeutics 2001, 297:458-466.
15. Bisoendial R.J., Tanck M.W., Golledge J., Broekhuizen L.N., Legemate D.A., Stroes E.S., et al. The association between the gene encoding 5-lipoxygenase activating protein and abdominal aortic aneurysms. Atherosclerosis 2011, 220:425-428.
16. 2 . Nature 1997, 390:622-625.
17. Boyce J.A. Mast cells and eicosanoid mediators: A system of reciprocal paracrine and autocrine regulation. Immunological Reviews 2007, 217:168-185.
18. Boyce J.A., Austen K.F. The biology of mast cells. Immunological diseases 2001, Lippincott Williams & Wilkins, Philadelphia. 6th ed. K.F. Austen (Ed.).
19. Cao R.Y., St Amand T., Grabner R., Habenicht A.J., Funk C.D. Genetic and pharmacological inhibition of the 5-lipoxygenase/leukotriene pathway in atherosclerotic lesion development in ApoE deficient mice. Atherosclerosis 2009, 203:395-400.
20. Carnini C., Accomazzo M.R., Borroni E., Vitellaro-Zuccarello L., Durand T., Folco G., et al. Synthesis of cysteinyl leukotrienes in human endothelial cells: Subcellular localization and autocrine signaling through the CysLT2 receptor. FASEB Journal 2011, 25:3519-3528.
21. Cederlund A., Gudmundsson G.H., Agerberth B. Antimicrobial peptides important in innate immunity. FEBS Journal 2011, 278:3942-3951.
22. Ceruti S., Villa G., Genovese T., Mazzon E., Longhi R., Rosa P., et al. The P2Y-like receptor GPR17 as a sensor of damage and a new potential target in spinal cord injury. Brain 2009, 132:2206-2218.
23. 4 receptor. American Journal of Respiratory Cell and Molecular Biology 2009, 42:294-303.
24. Cho Y.S., Song J.S., Huh J.Y., Kim C.H., Gong Y.D., Cheon H.G. Discovery of (2-fluoro-benzyl)-(2-methyl-2-phenethyl-2H-chromen-6-yl)-amine (KRH-102140) as an orally active 5-lipoxygenase inhibitor with activity in murine inflammation models. Pharmacology 2011, 87:49-55.
25. Ciana P., Fumagalli M., Trincavelli M.L., Verderio C., Rosa P., Lecca D., et al. The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. The EMBO Journal 2006, 25:4615-4627.
26. 2 . Journal of Lipid Mediators and Cell Signalling 1995, 12:83-117.
27. 4 mediates γδ T lymphocyte migration in response to diverse stimuli. Journal of Leukocyte Biology 2009, 87:323-332.
28. Dahlen S.E., Hedqvist P., Hammarstrom S., Samuelsson B. Leukotrienes are potent constrictors of human bronchi. Nature 1980, 288:484-486.
29. Daniele S., Lecca D., Trincavelli M.L., Ciampi O., Abbracchio M.P., Martini C. Regulation of PC12 cell survival and differentiation by the new P2Y-like receptor GPR17. Cellular Signalling 2010, 22:697-706.
30. 4 production in human atherosclerotic plaques. Biomedica Biochimica Acta 1988, 47:S182-S185.
31. 4 in up-regulation of CCR7 expression and function. Blood 2007, 109:626-631.
32. 2 enzymes: Physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chemical Reviews 2011, 111:6130-6185.
33. 2 reveals a novel topology and catalytic mechanism. Cell 1999, 97:349-360.
34. Di Gennaro A., Carnini C., Buccellati C., Ballerio R., Zarini S., Fumagalli F., et al. Cysteinyl-leukotrienes receptor activation in brain inflammatory reactions and cerebral edema formation: A role for transcellular biosynthesis of cysteinyl-leukotrienes. FASEB Journal 2004, 18:842-844.
35. 4 -induced changes in vascular permeability are mediated by neutrophil release of heparin-binding protein (HBP/CAP37/azurocidin). FASEB Journal 2009, 23:1750-1757.
36. 4 synthase and predominant formation of cysteinyl-leukotrienes in human abdominal aortic aneurysm. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:21093-21097.
37. 4 by epithelial fatty acid-binding protein in the rat basophilic leukemia cell. The Journal of Biological Chemistry 2004, 279:7420-7426.
38. Drazen J.M., Israel E., O'Byrne P.M. Treatment of asthma with drugs modifying the leukotriene pathway. The New England Journal of Medicine 1999, 340:197-206.
39. Dwyer J.H., Allayee H., Dwyer K.M., Fan J., Wu H., Mar R., et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. The New England Journal of Medicine 2004, 350:29-37.
40. Esser J., Gehrmann U., Salvado M.D., Wetterholm A., Haeggstrom J.Z., Samuelsson B., et al. Zymosan suppresses leukotriene C synthase activity in differentiating monocytes: Antagonism by aspirin and protein kinase inhibitors. FASEB Journal 2011, 25:1417-1427.
41. Evans J.F., Ferguson A.D., Mosley R.T., Hutchinson J.H. What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases. Trends in Pharmacological Sciences 2008, 29:72-78.
42. Ferguson A.D., McKeever B.M., Xu S., Wisniewski D., Miller D.K., Yamin T.T., et al. Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein. Science 2007, 317:510-512.
43. 4 to humans. The Journal of Infectious Diseases 2004, 189:2001-2009.
44. 4 triggers the in vitro and in vivo release of potent antimicrobial agents. Journal of Immunology 2007, 178:8036-8045.
45. Flodgaard H., Ostergaard E., Bayne S., Svendsen A., Thomsen J., Engels M., et al. Covalent structure of two novel neutrophile leucocyte-derived proteins of porcine and human origin. Neutrophile elastase homologues with strong monocyte and fibroblast chemotactic activities. European Journal of Biochemistry 1991, 197:535-547.
46. Folco G., Rossoni G., Buccellati C., Berti F., Maclouf J., Sala A. Leukotrienes in cardiovascular diseases. American Journal of Respiratory and Critical Care Medicine 2000, 161:S112-S116.
47. 4 , a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 1980, 286:264-265.
48. 4 induces release of antimicrobial peptides in lungs of virally infected mice. Journal of Immunology 2008, 180:6211-6221.
49. Gautam N., Olofsson A.M., Herwald H., Iversen L.F., Lundgren-Akerlund E., Hedqvist P., et al. Heparin-binding protein (HBP/CAP37): A missing link in neutrophil-evoked alteration of vascular permeability. Nature Medicine 2001, 7:1123-1127.
50. 4 , increased airway inflammatory cells in subjects with atopic asthma. American Journal of Respiratory and Critical Care Medicine 2001, 164:1495-1500.
51. Ge S., Zhou G., Cheng S., Liu D., Xu J., Xu G., et al. Anti-atherogenic effects of montelukast associated with reduced MCP-1 expression in a rabbit carotid balloon injury model. Atherosclerosis 2009, 205:74-79.
52. Gilbert N.C., Bartlett S.G., Waight M.T., Neau D.B., Boeglin W.E., Brash A.R., et al. The structure of human 5-lipoxygenase. Science 2011, 331:217-219.
53. 4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues. Nature Immunology 2003, 4:965-973.
54. 4 protects latently infected mice against murine cytomegalovirus reactivation following allogeneic transplantation. Journal of Immunology 2005, 174:1587-1593.
55. Greiner C., Hornig C., Rossi A., Pergola C., Zettl H., Schubert-Zsilavecz M., et al. 2-(4-(Biphenyl-4-ylamino)-6-chloropyrimidin-2-ylthio)octanoic acid (HZ52)-A novel type of 5-lipoxygenase inhibitor with favourable molecular pharmacology and efficacy in vivo. British Journal of Pharmacology 2011, 164:781-793.
56. Haeggstrom J.Z., Funk C.D. Lipoxygenase and leukotriene pathways: Biochemistry, biology, and roles in disease. Chemical Reviews 2011, 111:5866-5898.
57. Haeggstrom J.Z., Rinaldo-Matthis A., Wheelock C.E., Wetterholm A. Advances in eicosanoid research, novel therapeutic implications. Biochemical and Biophysical Research Communications 2010, 396:135-139.
58. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. The New England Journal of Medicine 2005, 352:1685-1695.
59. Hartiala J., Li D., Conti D.V., Vikman S., Patel Y., Tang W.H., et al. Genetic contribution of the leukotriene pathway to coronary artery disease. Human Genetics 2011, 129:617-627.
60. Hashimoto K., Ichiyama T., Hasegawa M., Hasegawa S., Matsubara T., Furukawa S. Cysteinyl leukotrienes induce monocyte chemoattractant protein-1 in human monocyte/macrophages via mitogen-activated protein kinase and nuclear factor-κB pathways. International Archives of Allergy and Immunology 2009, 149:275-282.
61. Hashimoto H., Miyazawa K., Hagiwara M., Miyasaka K., Nakashima M. Beneficial effects of a new 5-lipoxygenase inhibitor on occlusion- and occlusion-reperfusion-induced myocardial injury. Arzneimittel-Forschung 1990, 40:126-129.
62. Heise C.E., O'Dowd B.F., Figueroa D.J., Sawyer N., Nguyen T., Im D.S., et al. Characterization of the human cysteinyl leukotriene 2 receptor. The Journal of Biological Chemistry 2000, 275:30531-30536.
63. Helgadottir A., Manolescu A., Thorleifsson G., Gretarsdottir S., Jonsdottir H., Thorsteinsdottir U., et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nature Genetics 2004, 36:233-239.
64. 4 and BLT1 in smooth muscle cell recruitment. Circulation 2005, 112:578-586.
65. Henderson W.R., Chiang G.K., Tien Y.T., Chi E.Y. Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. American Journal of Respiratory and Critical Care Medicine 2006, 173:718-728.
66. 4 receptor antagonists as therapeutics for inflammatory disease: Preclinical and clinical developments. Expert Opinion on Investigational Drugs 2007, 16:1909-1920.
67. Hofmann B., Barzen S., Rodl C.B., Kiehl A., Borig J., Zivkovic A., et al. A class of 5-benzylidene-2-phenylthiazolinones with high potency as direct 5-lipoxygenase inhibitors. Journal of Medicinal Chemistry 2011, 54:1943-1947.
68. 4 as a major chemotactic factor released from the intraluminal thrombus. FASEB Journal 2009, 23:1376-1383.
69. Houard X., Touat Z., Ollivier V., Louedec L., Philippe M., Sebbag U., et al. Mediators of neutrophil recruitment in human abdominal aortic aneurysms. Cardiovascular Research 2009, 82:532-541.
70. 4 synthase expression by interleukin 4. The Journal of Experimental Medicine 2001, 193:123-133.
71. Hui Y., Yang G., Galczenski H., Figueroa D.J., Austin C.P., Copeland N.G., et al. The murine cysteinyl leukotriene 2 (CysLT2) receptor. cDNA and genomic cloning, alternative splicing, and in vitro characterization. The Journal of Biological Chemistry 2001, 276:47489-47495.
72. Hutchinson J.H., Li Y., Arruda J.M., Baccei C., Bain G., Chapman C., et al. 5-lipoxygenase-activating protein inhibitors: Development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2 -ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103). Journal of Medicinal Chemistry 2009, 52:5803-5815.
73. Ichiyama T., Hasegawa M., Ueno Y., Makata H., Matsubara T., Furukawa S. Cysteinyl leukotrienes induce monocyte chemoattractant protein 1 in human monocytes/macrophages. Clinical and Experimental Allergy 2005, 35:1214-1219.
74. Ichiyama T., Kajimoto M., Hasegawa M., Hashimoto K., Matsubara T., Furukawa S. Cysteinyl leukotrienes enhance tumour necrosis factor-α-induced matrix metalloproteinase-9 in human monocytes/macrophages. Clinical and Experimental Allergy 2007, 37:608-614.
75. 4 receptor BLT2 in murine inflammatory colitis. FASEB Journal 2010, 24:4678-4690.
76. Irvin C.G., Tu Y.P., Sheller J.R., Funk C.D. 5-Lipoxygenase products are necessary for ovalbumin-induced airway responsiveness in mice. The American Journal of Physiology 1997, 272:L1053-L1058.
77. 4 synthase. The Journal of Biological Chemistry 1996, 271:22203-22210.
78. Jakobsson P.J., Mancini J.A., Riendeau D., Ford-Hutchinson A.W. Identification and characterization of a novel microsomal enzyme with glutathione-dependent transferase and peroxidase activities. The Journal of Biological Chemistry 1997, 272:22934-22939.
79. Jawien J., Gajda M., Wolkow P., Zuranska J., Olszanecki R., Korbut R. The effect of montelukast on atherogenesis in apoE/LDLR-double knockout mice. Journal of Physiology and Pharmacology 2008, 59:633-639.
80. Jiang W., Hall S.R., Moos M.P., Cao R.Y., Ishii S., Ogunyankin K.O., et al. Endothelial cysteinyl leukotriene 2 receptor expression mediates myocardial ischemia-reperfusion injury. The American Journal of Pathology 2008, 172:592-602.
81. 4 receptor antagonist. Canadian Journal of Physiology and Pharmacology 1995, 73:191-201.
82. 4 inhibits EBV induced B-cell transformation in cord-blood derived mononuclear cultures. Immunology Letters 2008, 116:174-177.
83. Koch W., Hoppmann P., Mueller J.C., Schomig A., Kastrati A. No association of polymorphisms in the gene encoding 5-lipoxygenase-activating protein and myocardial infarction in a large central European population. Genetics in Medicine 2007, 9:123-129.
84. 4 antagonist with oral activity in the murine collagen-induced arthritis model. Journal of Medicinal Chemistry 1994, 37:3197-3199.
85. 4 in exhaled breath condensate and sputum supernatant in patients with COPD and asthma. Chest 2005, 127:1553-1559.
86. Krell R.D., Aharony D., Buckner C.K., Keith R.A., Kusner E.J., Snyder D.W., et al. The preclinical pharmacology of ICI 204,219. A peptide leukotriene antagonist. The American Review of Respiratory Disease 1990, 141:978-987.
87. Kristo F., Hardy G.J., Anderson T.J., Sinha S., Ahluwalia N., Lin A.Y., et al. Pharmacological inhibition of BLT1 diminishes early abdominal aneurysm formation. Atherosclerosis 2010, 210:107-113.
88. 4 receptor antagonist, LY293111Na, on leukocyte infiltration and collagen-induced arthritis in mice. European Journal of Pharmacology 2000, 402:275-285.
89. 4 -induced airway hyperresponsiveness of guinea pig tracheal smooth muscle to histamine and evidence for three separate sulfidopeptide leukotriene receptors. Proceedings of the National Academy of Sciences of the United States of America 1984, 81:4922-4925.
90. Lemaitre R.N., Rice K., Marciante K., Bis J.C., Lumley T.S., Wiggins K.L., et al. Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke. Atherosclerosis 2009, 204:e58-e63.
91. Lex C., Zacharasiewicz A., Payne D.N., Wilson N.M., Nicholson A.G., Kharitonov S.A., et al. Exhaled breath condensate cysteinyl leukotrienes and airway remodeling in childhood asthma: A pilot study. Respiratory Research 2006, 7:63.
92. 4 activates T cells that inhibit B-cell proliferation in EBV-infected cord blood-derived mononuclear cell cultures. Blood 2008, 111:2693-2703.
93. Liu D., Ge S., Zhou G., Xu G., Zhang R., Zhu W., et al. Montelukast inhibits matrix metalloproteinases expression in atherosclerotic rabbits. Cardiovascular Drugs and Therapy 2009, 23:431-437.
94. Luo M., Jones S.M., Phare S.M., Coffey M.J., Peters-Golden M., Brock T.G. Protein kinase A inhibits leukotriene synthesis by phosphorylation of 5-lipoxygenase on serine 523. The Journal of Biological Chemistry 2004, 279:41512-41520.
95. Lynch K.R., O'Neill G.P., Liu Q., Im D.S., Sawyer N., Metters K.M., et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 1999, 399:789-793.
96. Mackewicz C.E., Yuan J., Tran P., Diaz L., Mack E., Selsted M.E., et al α-Defensins can have anti-HIV activity but are not CD8 cell anti-HIV factors. AIDS 2003, 17:F23-F32.
97. 4 . Proceedings of the National Academy of Sciences of the United States of America 2009, 106:11685-11690.
98. 4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:16695-16700.
99. 4 augments neutrophil phagocytosis of Klebsiella pneumoniae. Infection and Immunity 2001, 69:2011-2016.
100. 4 synthase. Nature 2007, 448:613-616.
101. Mayranpaa M.I., Trosien J.A., Fontaine V., Folkesson M., Kazi M., Eriksson P., et al. Mast cells associate with neovessels in the media and adventitia of abdominal aortic aneurysms. Journal of Vascular Surgery 2009, 50:388-395.
102. Mehrabian M., Allayee H., Wong J., Shi W., Wang X.P., Shaposhnik Z., et al. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circulation Research 2002, 91:120-126.
103. Mellor E.A., Austen K.F., Boyce J.A. Cysteinyl leukotrienes and uridine diphosphate induce cytokine generation by human mast cells through an interleukin 4-regulated pathway that is inhibited by leukotriene receptor antagonists. The Journal of Experimental Medicine 2002, 195:583-592.
104. Mellor E.A., Frank N., Soler D., Hodge M.R., Lora J.M., Austen K.F., et al. Expression of the type 2 receptor for cysteinyl leukotrienes (CysLT2R) by human mast cells: Functional distinction from CysLT1R. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:11589-11593.
105. + T cells and airway hyperresponsiveness. The Journal of Immunology 2005, 174:4979-4984.
106. Moos M.P., Funk C.D. Endothelial cysteinyl leukotriene 2 receptor expression and myocardial ischemia/reperfusion injury. Trends in Cardiovascular Medicine 2008, 18:268-273.
107. Moos M.P., Mewburn J.D., Kan F.W., Ishii S., Abe M., Sakimura K., et al. Cysteinyl leukotriene 2 receptor-mediated vascular permeability via transendothelial vesicle transport. FASEB Journal 2008, 22:4352-4362.
108. 4 hydrolase: Protection from mechanism-based inactivation by mutation of tyrosine-378. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:5931-5935.
109. 4 synthase pathway in mouse mast cells. The Journal of Biological Chemistry 1995, 270:22653-22656.
110. Murakami M., Taketomi Y., Miki Y., Sato H., Hirabayashi T., Yamamoto K. Recent progress in phospholipase A research: From cells to animals to humans. Progress in Lipid Research 2011, 50:152-192.
111. Naik S., Billington C.K., Pascual R.M., Deshpande D.A., Stefano F.P., Kohout T.A., et al. Regulation of cysteinyl leukotriene type 1 receptor internalization and signaling. The Journal of Biological Chemistry 2005, 280:8722-8732.
112. Nakamura M., Shimizu T. Leukotriene receptors. Chemical Reviews 2011, 111:6231-6298.
113. 2+ -dependent gene expression. Nature 2012, 482:111-115.
114. Ni N.C., Yan D., Ballantyne L.L., Barajas-Espinosa A., St Amand T., Pratt D.A., et al. A selective cysteinyl leukotriene receptor 2 antagonist blocks myocardial ischemia/reperfusion injury and vascular permeability in mice. The Journal of Pharmacology and Experimental Therapeutics 2011, 339:768-778.
115. Nieves D., Moreno J.J. Role of 5-lipoxygenase pathway in the regulation of RAW 264.7 macrophage proliferation. Biochemical Pharmacology 2006, 72:1022-1030.
116. Obata T., Nambu F., Kitagawa T., Terashima H., Toda M., Okegawa T., et al. ONO-1078: An antagonist of leukotrienes. Advances in Prostaglandin, Thromboxane, and Leukotriene Research 1987, 17A:540-543.
117. 4 receptor 1. The Journal of Allergy and Clinical Immunology 2008, 121:864-871.
118. Okunishi K., Peters-Golden M. Leukotrienes and airway inflammation. Biochimica et Biophysica Acta 2011, 1810:1096-1102.
119. Oppenheim J.J., Yang D. Alarmins: Chemotactic activators of immune responses. Current Opinion in Immunology 2005, 17:359-365.
120. 4 . Nature Immunology 2003, 4:974-981.
121. 2 generation by human mast cells. The Journal of Biological Chemistry 2008, 283:16477-16487.
122. 4 -induced pulmonary inflammation is mediated by the P2Y12 receptor. The Journal of Experimental Medicine 2009, 206:2543-2555.
123. Paterson I.S., Smith F.C., Tsang G.M., Hamer J.D., Shearman C.P. Reperfusion plasma contains a neutrophil activator. Annals of Vascular Surgery 1993, 7:68-75.
124. 4 ) hydrolase as potential anti-inflammatory agents. Current Pharmaceutical Design 2001, 7:163-179.
125. Pergola C., Rogge A., Dodt G., Northoff H., Weinigel C., Barz D., et al. Testosterone suppresses phospholipase D, causing sex differences in leukotriene biosynthesis in human monocytes. The FASEB Journal 2011, 25:3377-3387.
126. Peters-Golden M., Henderson W.R. Leukotrienes. The New England Journal of Medicine 2007, 357:1841-1854.
127. Poeckel D., Funk C.D. The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular disease. Cardiovascular Research 2010, 86:243-253.
128. Poeckel D., Zemski Berry K.A., Murphy R.C., Funk C.D. Dual 12/15- and 5-lipoxygenase deficiency in macrophages alters arachidonic acid metabolism and attenuates peritonitis and atherosclerosis in ApoE knock-out mice. The Journal of Biological Chemistry 2009, 284:21077-21089.
129. 4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:8161-8166.
130. 4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton. The Journal of Pharmacology and Experimental Therapeutics 2007, 321:1154-1160.
131. 4 hydrolase inhibition attenuates allergic airway inflammation and hyperresponsiveness. American Journal of Respiratory and Critical Care Medicine 2010, 181:899-907.
132. 4 antagonists in the mouse ear edema and rat neutropenia models. Inflammation Research 1995, 44(Suppl 2):S141-S142.
133. Revermann M., Mieth A., Popescu L., Paulke A., Wurglics M., Pellowska M., et al. A pirinixic acid derivative (LP105) inhibits murine 5-lipoxygenase activity and attenuates vascular remodelling in a murine model of aortic aneurysm. British Journal of Pharmacology 2011, 163:1721-1732.
134. 4 synthase expression in the monocyte-like cell line, THP-1. The Journal of Immunology 1999, 162:1101-1107.
135. 4 synthase. The Journal of Biological Chemistry 2010, 285:40771-40776.
136. 4 transporter MRP1 regulates CCL19 (MIP-3β, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell 2000, 103:757-768.
137. Rossi A., Cuzzocrea S., Sautebin L. Involvement of leukotriene pathway in the pathogenesis of ischemia-reperfusion injury and septic and non-septic shock. Current Vascular Pharmacology 2009, 7:185-197.
138. Rossoni G., Sala A., Berti F., Testa T., Buccellati C., Molta C., et al. Myocardial protection by the leukotriene synthesis inhibitor BAY X1005: Importance of transcellular biosynthesis of cysteinyl-leukotrienes. The Journal of Pharmacology and Experimental Therapeutics 1996, 276:335-341.
139. Rudberg P.C., Tholander F., Thunnissen M.M., Haeggstrom J.Z. Leukotriene A4 hydrolase/aminopeptidase. Glutamate 271 is a catalytic residue with specific roles in two distinct enzyme mechanisms. The Journal of Biological Chemistry 2002, 277:1398-1404.
140. 4 plays a pivotal role in CD40-dependent activation of chronic B lymphocytic leukemia cells. Blood 2005, 105:1274-1279.
141. 4 synthase with two arginine residues. The Journal of Biological Chemistry 2011, 286:16392-16401.
142. Sala A., Rossoni G., Berti F., Buccellati C., Bonazzi A., Maclouf J., et al. Monoclonal anti-CD18 antibody prevents transcellular biosynthesis of cysteinyl leukotrienes in vitro and in vivo and protects against leukotriene-dependent increase in coronary vascular resistance and myocardial stiffness. Circulation 2000, 101:1436-1440.
143. Samuelsson B., Dahlen S.E., Lindgren J.A., Rouzer C.A., Serhan C.N. Leukotrienes and lipoxins: Structures, biosynthesis, and biological effects. Science 1987, 237:1171-1176.
144. 4 enhances the activity of nuclear factor-κB pathway through BLT1 and BLT2 receptors in atherosclerosis. Cardiovascular Research 2009, 81:216-225.
145. 4 biosynthesis. Journal of Medicinal Chemistry 2010, 53:573-585.
146. 4 synthase gene expression in the monocyte-like cell line, THP-1. American Journal of Respiratory Cell and Molecular Biology 2000, 23:234-240.
147. Shafer W.M., Martin L.E., Spitznagel J.K. Cationic antimicrobial proteins isolated from human neutrophil granulocytes in the presence of diisopropyl fluorophosphate. Infection and Immunity 1984, 45:29-35.
148. 4 via microsomal glutathione S-transferase type 2 and express the CysLT1 receptor. European Journal of Biochemistry 2001, 268:2578-2586.
149. Sjostrom M., Johansson A.S., Schroder O., Qiu H., Palmblad J., Haeggstrom J.Z. Dominant expression of the CysLT2 receptor accounts for calcium signaling by cysteinyl leukotrienes in human umbilical vein endothelial cells. Arteriosclerosis, Thrombosis, and Vascular Biology 2003, 23:e37-e41.
150. 4 H in limiting chronic pulmonary neutrophilic inflammation. Science 2010, 330:90-94.
151. Soehnlein O., Xie X., Ulbrich H., Kenne E., Rotzius P., Flodgaard H., et al. Neutrophil-derived heparin-binding protein (HBP/CAP37) deposited on endothelium enhances monocyte arrest under flow conditions. The Journal of Immunology 2005, 174:6399-63405.
152. + hematopoietic progenitors and in lymphoid organs. Blood 2000, 96:3857-3865.
153. Stock N.S., Bain G., Zunic J., Li Y., Ziff J., Roppe J., et al. 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors. Part 4: Development of 3-[3-tert-Butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyri din-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic Acid (AM803), a Potent, Oral, Once Daily FLAP Inhibitor. Journal of Medicinal Chemistry 2011, 54:8013-8029.
154. 4 receptors in the development of atherosclerosis: Potential mechanisms. Arteriosclerosis, Thrombosis, and Vascular Biology 2004, 24:369-375.
155. 4 receptor BLT1 mediates early effector T cell recruitment. Nature Immunology 2003, 4:982-990.
156. Takasaki J., Kamohara M., Matsumoto M., Saito T., Sugimoto T., Ohishi T., et al. The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT2 receptor. Biochemical and Biophysical Research Communications 2000, 274:316-322.
157. 4 during myocardial ischemia in humans. Clinical Cardiology 1996, 19:198-204.
158. Tardif J.C., L'Allier P.L., Ibrahim R., Gregoire J.C., Nozza A., Cossette M., et al. Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circulation: Cardiovascular Imaging 2010, 3:298-307.
159. 4 receptor 1 confers resistance to airway hyperresponsiveness and Th2-type immune responses. The Journal of Immunology 2005, 175:4217-4225.
160. 4 hydrolase, a bifunctional enzyme in inflammation. Nature Structural Biology 2001, 8:131-135.
161. 4 receptor 1. Biochimie 2010, 92:682-691.
162. 4 hydrolase inhibitor, and indomethacin on carrageenan-induced murine dermatitis. European Journal of Pharmacology 1998, 346:81-85.
163. 2 in allergic response and parturition. Nature 1997, 390:618-622.
164. Uzonyi B., Lotzer K., Jahn S., Kramer C., Hildner M., Bretschneider E., et al. Cysteinyl leukotriene 2 receptor and protease-activated receptor 1 activate strongly correlated early genes in human endothelial cells. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:6326-6331.
165. van Rensen E.L., Sont J.K., Evertse C.E., Willems L.N., Mauad T., Hiemstra P.S., et al. Bronchial CD8 cell infiltrate and lung function decline in asthma. American Journal of Respiratory and Critical Care Medicine 2005, 172:837-841.
166. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovascular Research 2004, 61:481-497.
167. 4 and resolvin E1. FASEB Journal 2011, 25:1697-1705.
168. 4 triggers release of the cathelicidin LL-37 from human neutrophils: Novel lipid-peptide interactions in innate immune responses. FASEB Journal 2007, 21:2897-2905.
169. 4 receptors on human airway smooth muscle cells. The Journal of Allergy and Clinical Immunology 2009, 124:59-65.
170. 4 , an activation product of mast cells, is a chemoattractant for their progenitors. The Journal of Experimental Medicine 2005, 201:1961-1971.
171. Werz O., Burkert E., Samuelsson B., Radmark O., Steinhilber D. Activation of 5-lipoxygenase by cell stress is calcium independent in human polymorphonuclear leukocytes. Blood 2002, 99:1044-1052.
172. Werz O., Klemm J., Samuelsson B., Radmark O. 5-lipoxygenase is phosphorylated by p38 kinase-dependent MAPKAP kinases. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:5261-5266.
173. Werz O., Szellas D., Steinhilber D., Radmark O. Arachidonic acid promotes phosphorylation of 5-lipoxygenase at Ser-271 by MAPK-activated protein kinase 2 (MK2). The Journal of Biological Chemistry 2002, 277:14793-14800.
174. 4 hydrolase. British Journal of Pharmacology 2008, 153:983-991.
175. 4 increases nasal neutrophil activity and conditions neutrophils to exert antiviral effects. Respiratory Medicine 2011, 105:997-1006.
176. Wisniewska J.M., Rodl C.B., Kahnt A.S., Buscato E., Ulrich S., Tanrikulu Y., et al. Molecular characterization of EP6-A novel imidazo[1,2-a]pyridine based direct 5-lipoxygenase inhibitor. Biochemical Pharmacology 2011, 83:228-240.
177. Woods J.W., Coffey M.J., Brock T.G., Singer I.I., Peters-Golden M. 5-Lipoxygenase is located in the euchromatin of the nucleus in resting human alveolar macrophages and translocates to the nuclear envelope upon cell activation. The Journal of Clinical Investigation 1995, 95:2035-2046.
178. Wunder F., Tinel H., Kast R., Geerts A., Becker E.M., Kolkhof P., et al. Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT2) receptor. British Journal of Pharmacology 2010, 160:399-409.
179. 4 , in calcium reporter and β arrestin assays. Molecular Pharmacology 2011, 79:270-278.
180. Yellon D.M., Hausenloy D.J. Myocardial reperfusion injury. The New England Journal of Medicine 2007, 357:1121-1135.
181. 4 that mediates chemotaxis. Nature 1997, 387:620-624.
182. 4 receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. The Journal of Experimental Medicine 2000, 192:421-432.
183. Zhao L., Moos M.P., Grabner R., Pedrono F., Fan J., Kaiser B., et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nature Medicine 2004, 10:966-973.